Senseonics Holdings, Inc. 8-K

What Happened

• On April 30, 2026 Senseonics Holdings, Inc. (SENS) entered an underwriting agreement to sell 8,000,000 shares of common stock and 8,000,000 pre‑funded warrants (each exercisable for one share) at $5.00 per share (or $4.999 per pre‑funded warrant). The underwriters have a 30‑day option to buy up to 2,400,000 additional shares. Net proceeds are expected to be about $74.745 million (about $86.025 million if the option is fully exercised). The offering closing is expected on May 4, 2026 and was priced/prompted by press releases on April 30, 2026.
• Separately, Senseonics provided preliminary (unaudited) results for the quarter ended March 31, 2026: revenue ~ $11.7 million, gross profit ~ $6.4 million (gross margin ~54%), an expected net loss of $31–33 million, cash and equivalents and short‑term investments of ~ $64.6 million, and stockholders’ equity of ~$33.7–35.7 million. Final results are scheduled for public release on May 7, 2026.

Key Details

• Offering: 8,000,000 shares + 8,000,000 pre‑funded warrants at $5.00/$4.999; 30‑day option for up to 2,400,000 additional shares. Expected net proceeds ≈ $74.745M (≈ $86.025M if option exercised).
• Preliminary Q1 2026 metrics: revenue ≈ $11.7M; gross profit ≈ $6.4M (54% margin); net loss $31–33M; cash & equivalents ≈ $64.6M.
• Liquidity development: Senseonics’ unitary borrower (Senseonics, Inc.) entered a non‑binding term sheet with Hercules Capital to amend its loan facility, potentially raising facility capacity from $100M to $140M; $35M currently outstanding. Proposed near‑term commitments total $20M (a $10M advance at amendment closing and a $10M commitment available through Sept. 15, 2026 subject to a capital‑raising milestone expected to be met by the offering).
• Corporate disclosure: Pricing and commencement press releases dated April 30, 2026 were furnished as Exhibits; offering is being made under an effective Form S‑3 shelf.

Why It Matters

• Cash and runway: The equity offering, together with the proposed Hercules facility amendment, are material steps to increase Senseonics’ available liquidity. The expected net proceeds (~$74.7M to $86.0M) could significantly affect the company’s cash position beyond the reported ~$64.6M on hand at quarter end.
• Dilution and structure: The sale of shares and pre‑funded warrants will dilute existing shareholders when shares are issued or warrants exercised; pre‑funded warrants are often used to accommodate purchasers who need to limit voting/ownership but still secure economic exposure.
• Financial health: Preliminary Q1 numbers show continued revenue but a sizable net loss ($31–33M). These are unaudited estimates and may change when final results are released on May 7, 2026—investors should review the formal earnings release and the final 10‑Q when available.
• Next steps for investors: Watch for the May 4 offering close and the May 7 full Q1 release; monitor whether the underwriters exercise the overallotment and whether the Hercules amendment is finalized (the term sheet is non‑binding).